Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
暂无分享,去创建一个
A. Osterhaus | J. Aerts | P. Lacor | C. Heirman | K. Thielemans | K. Breckpot | A. Bonehill | A. Michiels | R. Gruters | Katrien Pletinckx | S. Allard | C. V. van Baalen
[1] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[2] E. Rosenberg,et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. , 2006, Blood.
[3] Bernard Verrier,et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. , 2006, Blood.
[4] C. Rouzioux,et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals , 2006, AIDS.
[5] L. Dorrell. Therapeutic immunization strategies for the control of HIV-1 , 2005, Expert review of vaccines.
[6] C. Heirman,et al. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy , 2005, The journal of gene medicine.
[7] Felipe García,et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. , 2005, The Journal of infectious diseases.
[8] F. Brasseur,et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.
[9] A. Palucka,et al. Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.
[10] A. Órfão,et al. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection , 2005, AIDS.
[11] Wei Lu,et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection , 2004, Nature Medicine.
[12] R. Koup,et al. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know , 2004, Nature Medicine.
[13] Todd M. Allen,et al. HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α , 2004 .
[14] E. Gilboa,et al. Cancer immunotherapy with mRNA‐transfected dendritic cells , 2004, Immunological reviews.
[15] F. Brasseur,et al. Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.
[16] L. B. de Arruda,et al. DNA vaccine encoding human immunodeficiency virus‐1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal‐associated membrane protein, elicits enhanced long‐term memory response , 2004, Immunology.
[17] G. Pantaleo,et al. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. , 2004, Blood.
[18] C. Heirman,et al. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells , 2003, Cancer Gene Therapy.
[19] B. Walker,et al. Therapeutic vaccines against HIV need international partnerships , 2003, Nature Reviews Immunology.
[20] O. Yang. Will we be able to 'spot' an effective HIV-1 vaccine? , 2003, Trends in immunology.
[21] M. Baalen,et al. Impact of antigen expression kinetics on the effectiveness of HIV‐specific cytotoxic T lymphocytes , 2002, European journal of immunology.
[22] J. Tartaglia,et al. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. , 2002, Vaccine.
[23] A. Osterhaus,et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. , 2002, Vaccine.
[24] C. Broeckhoven,et al. mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation , 2002, Leukemia.
[25] Kris Thielemans,et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.
[26] D. Richman,et al. Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression , 2002, AIDS.
[27] M. Robert-Guroff,et al. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. , 2001, Immunology letters.
[28] C. van Broeckhoven,et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.
[29] J. Lieberman,et al. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. , 2000, Blood.
[30] V. Calvez,et al. Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 , 2000, The Journal of Immunology.
[31] Douglas D. Richman,et al. HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.
[32] H. Kessler,et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. , 1999, Journal of immunology.
[33] C. Pitcher,et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.
[34] Spyros A. Kalams,et al. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.
[35] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[36] F. Miedema,et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. , 1997, The Journal of general virology.
[37] Brian Seed,et al. Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.
[38] M. Malim,et al. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain , 1991, Journal of virology.
[39] C. Debouck,et al. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat , 1990, The Journal of cell biology.
[40] M. Malim,et al. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein , 1989, Journal of virology.
[41] S. Josephs,et al. Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[42] V. Ovod,et al. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines , 2005, Archives of Virology.
[43] J. Lieberman,et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. , 2003, Blood.
[44] C. Kuiken,et al. HIV sequence databases. , 2003, AIDS reviews.
[45] P. Easterbrook,et al. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. , 2002, Journal of immunology.